Literature DB >> 12552034

Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy.

M J Eikelenboom1, A Petzold, R H C Lazeron, E Silber, M Sharief, E J Thompson, F Barkhof, G Giovannoni, C H Polman, B M J Uitdehaag.   

Abstract

OBJECTIVE: To evaluate markers of axonal damage in CSF and serum of patients with different subtypes of MS in relation to measures of disease progression on MRI.
METHODS: In 51 patients with MS (21 relapsing-remitting, 20 secondary progressive, 10 primary progressive), levels of heavy and light neurofilaments (NfH and NfL) and antibodies to neurofilaments (anti-NfL and -NfH) as well as the total immunoglobulin G (IgG) were analyzed. MRI analysis included T2 hyperintense, T1 hypointense, and gadolinium enhancing lesions and markers of cerebral atrophy (ventricular and parenchymal fractions).
RESULTS: For the total group, correlations were found between the anti-NfL index and the parenchymal fraction (PF) (r = -0.51, p < 0.001), T2 lesion load (r = 0.41, p < 0.05), ventricular fraction (r = 0.37, p < 0.05), and T1 lesion load (r = 0.37, p < 0.05). For the anti-NfH index, a correlation was found with the PF (r = -0.39, p < 0.05). No correlations were found between the IgG index and MRI measures.
CONCLUSIONS: Intrathecal production of anti-NfL antibodies may serve as a marker of tissue damage, particularly axonal loss, in MS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12552034     DOI: 10.1212/01.wnl.0000041496.58127.e3

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  31 in total

Review 1.  Early-stage multiple sclerosis : what are the treatment options?

Authors:  Per Soelberg Sorensen
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 2.  Humoral immunity in multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis.

Authors:  Anne H Cross; Jennifer L Stark
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 3.  Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases.

Authors:  Nabil K El Ayoubi; Samia J Khoury
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

4.  Peripheral VH4+ plasmablasts demonstrate autoreactive B cell expansion toward brain antigens in early multiple sclerosis patients.

Authors:  Jacqueline R Rivas; Sara J Ireland; Rati Chkheidze; William H Rounds; Joseph Lim; Jordan Johnson; Denise M O Ramirez; Ann J Ligocki; Ding Chen; Alyssa A Guzman; Mark Woodhall; Patrick C Wilson; Eric Meffre; Charles White; Benjamin M Greenberg; Patrick Waters; Lindsay G Cowell; Ann M Stowe; Nancy L Monson
Journal:  Acta Neuropathol       Date:  2016-10-11       Impact factor: 17.088

5.  Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study.

Authors:  A Petzold; M J Eikelenboom; G Keir; D Grant; R H C Lazeron; C H Polman; B M J Uitdehaag; E J Thompson; G Giovannoni
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-02       Impact factor: 10.154

6.  Association Between Serum MicroRNAs and Magnetic Resonance Imaging Measures of Multiple Sclerosis Severity.

Authors:  Keren Regev; Brian C Healy; Fariha Khalid; Anu Paul; Renxin Chu; Shahamat Tauhid; Subhash Tummala; Camilo Diaz-Cruz; Radhika Raheja; Maria A Mazzola; Felipe von Glehn; Pia Kivisakk; Sheena L Dupuy; Gloria Kim; Tanuja Chitnis; Howard L Weiner; Roopali Gandhi; Rohit Bakshi
Journal:  JAMA Neurol       Date:  2017-03-01       Impact factor: 18.302

7.  Brain antigens in functionally distinct antigen-presenting cell populations in cervical lymph nodes in MS and EAE.

Authors:  Marloes van Zwam; Ruth Huizinga; Marie-José Melief; Annet F Wierenga-Wolf; Marjan van Meurs; Jane S Voerman; Knut P H Biber; Hendrikus W G M Boddeke; Uta E Höpken; Christian Meisel; Andreas Meisel; Ingo Bechmann; Rogier Q Hintzen; Bert A 't Hart; Sandra Amor; Jon D Laman; Leonie A Boven
Journal:  J Mol Med (Berl)       Date:  2008-12-03       Impact factor: 4.599

Review 8.  Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making.

Authors:  Violaine K Harris; Saud A Sadiq
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

9.  Autoantibodies to Non-myelin Antigens as Contributors to the Pathogenesis of Multiple Sclerosis.

Authors:  Michael C Levin; Sangmin Lee; Lidia A Gardner; Yoojin Shin; Joshua N Douglas; Chelsea Cooper
Journal:  J Clin Cell Immunol       Date:  2013-06-30

10.  The Validation Study of Neurofilament Heavy Chain and 8-hydroxy-2'-deoxyguanosine as Plasma Biomarkers of Clinical/Paraclinical Activity in First and Relapsing-Remitting Demyelination Acute Attacks.

Authors:  S Ljubisavljevic; I Stojanovic; J Basic; D A Pavlovic
Journal:  Neurotox Res       Date:  2016-06-13       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.